Evidence map›Paper›PMID 34251535›Full record

ArticleClinical oral investigations2022

Salivary IL-8 as a putative predictive biomarker of radiotherapy response in head and neck cancer patients.

Sara Principe, Enrique Zapater-Latorre, Leo Arribas, Enrique Garcia-Miragall, Jose Bagan

Abstract read
In one paragraph

Article in Clinical oral investigations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara PrincipeFaculty of Medicine and Dentistry, University of Valencia, Fundación Investigación Hospital General Universitari (FiHgU) de Valencia, Valencia, Spain.
Enrique Zapater-LatorreUniversity of Valencia, Hospital General Universitari de Valencia, Valencia, Spain.
Leo ArribasDepartment of Radiation Oncology, Fundación Instituto Valenciano de Oncologia, Valencia, Spain.
Enrique Garcia-MiragallService of Radiation Oncology, Hospital General Universitari de Valencia, Valencia, Spain.
Jose BaganOral Medicine, Stomatology and Maxillofacial Surgery, University of Valencia, CIBERONC, PI19/00790 Fondo de Investigacion Sanitaria, ISCIII, Hospital General Universitari de Valencia, Avda Tres Cruces, 2, 46014, Valencia, Spain. bagan@uv.es.ORCID http://orcid.org/0000-0002-0295-2916

Funding

H2020 Marie Skłodowska-Curie Actions () 721906
6 · The paper itself

Abstract

objectivesIonizing radiation increases the expression of a number of salivary proteins involved in immunoregulatory networks related to infection, injury, inflammation, and cancer. Our main objective was to analyze whether there are significant differences in salivary cytokines before and after radiotherapy and whether any of them are associated to better outcomes after radiotherapy serving as a potential predictive biomarker of response to the treatment. MATERIALS AND

methodsWe analyzed a panel of eight salivary markers (IL-4, IL-6, IL-8, and IL-10; MCP-1; TNF-α; VEGF; and EGF) in a group of HNC patients (N = 30), before and after irradiation treatment pre- and post-RT. We also compared these results with a group of healthy controls (N = 37). In both groups, we used stimulated saliva and we performed immunoassays based on multi-analyte profiling technology (Luminex xMAP).

resultsIn our group of 30 HNC patients, 24 of them showed a good clinical response after radiotherapy treatment while 6 cases did not respond to radiotherapy. The data revealed a post-treatment increase in multiple cytokines in the stimulated saliva of HNC patients; the increases in IL-8 and MCP-1 were statistically significant (p ≤ 0.001 and p ≤ 0.0001, respectively). Analysis of receiver operating characteristic curves indicated the strong potential of IL-8 as a predictive biomarker of RT good outcomes (area under the curve = 0.84; p = 0.018).

conclusionsAfter analyzing the panel of salivary cytokines, IL-8 showed the best association to the response to radiotherapy; in this sense, low IL-8 levels in the saliva of HNC patients before receiving irradiation therapy are associated with positive RT outcomes. CLINICAL RELEVANCE: Salivary IL-8 expression in HNC patients undergoing RT may serve as a potential predictive biomarker of response to the treatment.

Indexed as

Head and Neck NeoplasmsInterleukin-8Biomarkers, TumorCytokinesHumansSalivaBiomarkers, TumorCXCL8 protein, humanCytokinesInterleukin-8CytokinesHead and neck cancerIL-8RadiotherapySaliva

Identifiers

PMID34251535
PMCPMC8791883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.